Article
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
BigField GEG Tech's insight:
First 3 of 15 patients treated with LentiGlobin achieved higher drug product vector copy number and lentiviral-vector-positive–cell production after a change in manufacturing process.
Two patients with advanced metastatic colorectal cancer achieved disease stability after receiving Celyad's NKR-2 CAR T-cell therapy.
BigField GEG Tech's insight:
New data from the Phase 1 THINK clinical trial (NCT03018405) show that two metastatic colorectal cancer (mCRC) patients whose disease progressed following at least two prior therapies had stabilized the disease at a three-month follow-up after receiving the lowest dose level of Celyad’s NKR-2 CAR T-cell therapy.
BigField GEG Tech's insight:
Researchers at Seattle Children’s Hospital have launched a first-in-human trial to investigate whether infusions of T-cell antigen–presenting cells prolong the persistence of chimeric antigen receptor T-cell immunotherapy among children with relapsed or refractory acute lymphoblastic leukemia or lymphoma.
BigField GEG Tech's insight:
Here, the authors have ablated the CCR5 and CXCR4 genes in human CD4+ cell lines and primary CD4+ T cells, simultaneously, using CRISPR/Cas9. The efficiency of gene modification is as high as 55% for CCR5 and 36% for CXCR4 in CD4+ cell lines through transduction of a single lentiviral vector (LV-X4R5). Moreover LV-X4R5 disrupted over 12% of CCR5 and 10% of CXCR4 in primary human CD4+ T cells, which were rendered resistant to HIV-1 NL4-3 and HIV-1 YU-2 in vitro. Their results demonstrate the efficacy of CRISPR/Cas9 in multiplex gene modification on peripherally circulating CD4+ T cells, which may used to design functional cure for HIV-1 infection.
BigField GEG Tech's insight:
In this chapter the authors discuss the manufacture of pseudotyped lentiviral vector with an emphasis on small-scale laboratory grade production.
Counsell and colleagues have developed a novel lentiviral vector, LTR1, designed to
BigField GEG Tech's insight:
Here, the scientists describe the development of a novel lentiviral vector (LTR1) with a unique genomic structure designed to prevent transfer of HIV-1 packaging sequences to patient cells, thus reducing the total HIV-1 content to just 4.8% of the wild-type genome. This has been achieved by reconfiguring the vector to mediate reverse-transcription with a single strand transfer, instead of the usual two, and in which HIV-1 packaging sequences are not copied.
BigField GEG Tech's insight:
Two teams of scientists have used lentiviral vectors to generate blood stem cells by reprogramming either human or mouse cells. In both cases, these hematopoietic stem cells successfully produced blood cells when implanted into mice.
BigField GEG Tech's insight:
In this study, the scientists demonstrate that anchorage of lentiviral vector-transduced bone marrow-derived mesenchymal stem cells (BMMSCs), which co-overexpressed both BDNF and VEGF in the hippocampus and temporal cortex along with significantly ameliorated brain pathology and improved neurofunctional performance in CA-GCII rats after transplantation. These findings provide a proof of concept for the further validation of engineered BMMSCs for the treatment of CA-GCII patients in clinical practice in the future.
BigField GEG Tech's insight:
In this review, the authors discuss the current development of CRISPR/Cas9 technologies for therapeutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. Different methods used to facilitate efficient CRISPR delivery and gene editing in T cells are compared. They also address the safety concerns associated with the use of CRISPR/Cas9 gene editing and provide potential solutions and future directions of CRISPR application in the field of CAR T cell immunotherapy.
BigField GEG Tech's insight:
In this Review, the authors discuss the technical aspects of genome-scale knockout screens using CRISPR–Cas technology, and they compare these screens with alternative genetic screening technologies. The relative ease of use and reproducibility of CRISPR–Cas make it a powerful tool for probing virus–host interactions and for identifying new antiviral targets.
BigField GEG Tech's insight:
Optogenetics is a new biological technique that allows reversible modulation of electrical function with unmatched spatiotemporal precision using light-gated ion channels. Here, the authors investigated optogenetic manipulation of anatomical re-entry in ventricular cardiac tissue.
Our constant innovation process has led us to develop more efficient tools and to enlarge application fields of lentiviral vector technology.
BigField GEG Tech's insight:
Launching an open innovation strategy required a fundamental change in the way we worked. We first had to work on R&D to adapt our technology to a variety of innovation contexts. In parallel, we designed an online platform to transparently share hundreds of vector technologies, as well as prices and other relevant data. The GEG-tech platform now offers more than 5’000 vectorization systems. Actually not enough, since many clients have specific requirements outside the catalog. Open innovation also involves sharing insights and methods to enhance our client’s innovation performance.
https://www.geg-tech.com/about-us/references
|
BigField GEG Tech's insight:
Successful vaccines need to deliver antigen as well as stimulate the immune response. Kim et al . examine the mechanisms by which dendritic cell (DC)–targeting lentiviral vectors (LVs) accomplish both of these goals. They found that transduction was not required and that pseudotransduction was sufficient for antigen delivery and immune stimulation. The authors identified two mechanisms behind this effect: Viral fusion induced a PI3K-dependent immune stimulation pathway, and human genomic DNA within the virion preparations activated the STING/cGAS pathway. These data suggest that STING and cGAS agonists could serve as potential vaccine adjuvants
BigField GEG Tech's insight:
The past several years have seen tremendous advances in the engineering of immune
BigField GEG Tech's insight:
This special report discusses the concept of exploiting natural killer cell receptors as an approach that could broaden the specificity of CAR T cells and potentially enhance the efficacy of this therapy against solid tumors. New data demonstrating feasibility of this approach in humans and supporting the ongoing clinical trial are also presented.
BigField GEG Tech's insight:
Precise determination of tumour growth is a prerequisite for estimating the functional importance of tumour suppressor alterations in cancer. A study in Nature Methods now describes the development of Tuba-seq, an approach that integrates tumour barcoding with high-throughput sequencing, to precisely quantify the size of individual tumours in vivo.
The new method relies on the use of lentiviral Cre-vector libraries that contain DNA barcodes to stably tag individual lesions with a unique identifier. In a genetically engineered mouse model of human lung cancer, transduction of lung epithelial cells leads to Cre recombinase-mediated expression of oncogenic Kras. Expression of this oncogene induces the simultaneous development of multiple tumours, each now tagged with a unique 15-nucleotide (nt) barcode. In a first set of experiments, the Kras-driven tumours were analysed side-by-side with lung tumours that carried additional deficiencies in the tumour suppressor genes Lkb1 or p53. High-throughput sequencing was performed on bulk tumour DNA, and read counts from barcodes were converted to estimated cell numbers based on mixed-in 'benchmark' cells. Tuba-seq accurately determined the number of neoplastic cells in all tumours in parallel, finding them to be more than 1,000-fold different in cell number. The size distribution of tumours further provided insight into the different mechanisms of action of p53 and LKB1 (also known as STK11) in suppressing tumour growth.
Having demonstrated the utility of Tuba-seq, Rogers, McFarland, Winters et al. set out to adapt the method for multiplexing, this time using CRISPR–Cas9-mediated inactivation of 11 known or suspected tumour suppressors in the Kras-driven lung adenocarcinoma model. Lentiviral vectors carried an 8-nt tag specific for an encoded guide RNA, as well as the 15-nt barcode for cancer cell quantification. In this experimental setup, in which different tumour suppressor genotypes were present within the same mouse, size and genotype of tumours were simultaneously determined by sequencing the guide RNA-specific barcode tag. Lkb1, Rb1, Cdkn2a and Apc were confirmed as tumour suppressors in Kras-driven lung cancer growth, and novel potential lung tumour suppressors (splicing factor Rbm10 and the methyltransferase Setd2) were found.
With its exceptional level of precision and reproducibility, Tuba-seq will be a powerful tool to determine the impact of loss-of-function mutations on tumour growth in vivo. Moreover, this approach can likely be adapted to other types of cancers and scaled up to even more extensively multiplexed libraries.
BigField GEG Tech's insight:
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal and mutant HTT is a promising therapeutic approach. In a first study, the authors developed a lentiviral vector (LV) expressing a shRNA to downregulated HTT and observed a reduction of pathology in an HD rodent model. In this new study, they modified the design of the LV for preclinical development by using a tat independent third-generation LV (pCCL) backbone and removing the original reporter genes. They tested the efficiency of their new LV shHTT6 in vitrowith Striatal Neurons Derived from HD-iPSCs and in vivo by LV injection in the striatum of adult mice. They also investigated several parameters concerning the biosafety:
Their results demonstrated the reduction of two major pathological hallmarks for HD, a minimal inflammatory response in the brain, proper cellular processing of the shRNA, and a highly favorable on/off-target profile. These preclinical data suggest that this new shRNA vector fulfills primary biosafety and efficiency requirements for further development in the clinic as a cure for HD. GEG Tech provides a large range of fully customizable LV to express your favorite transgenes, including for shRNA. By the way, GEG Tech is born in a laboratory of neurology, the first laboratory which done gene transfers in the brain. Consequently, GEG has a high expertise in the design of gene transfer tools in this field and offers solutions allowing to have specific and/or inducible expression in astrocytes, microglia cells, neurons and in some cases in some subpopulations of neurons.
To know more about the Article To know more about shRNA LV To know more about GEG Tech
BigField GEG Tech's insight:
Researchers have identified two groups of neurons that can be turned on and off to alleviate the movement-related symptoms of Parkinson's disease. The activation of these cells in the basal ganglia relieves symptoms for much longer than current therapies, like deep brain stimulation and pharmaceuticals. The study, completed in a mouse model of Parkinson's, used optogenetics to better understand the neural circuitry involved in Parkinson's disease, and could provide the basis for new experimental treatment protocols.
BigField GEG Tech's insight:
Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. To target hematologic malignancies with a chimeric antigen receptor (CAR) that targets two antigens with a single vector, and thus potentially lessen the chance of leukemic escape mutations, a tandem-CAR approach was investigated.
BigField GEG Tech's insight:
Treatments for bone nonunions (fractures that fail to heal) include surgery and bone grafting. As an alternative to viral gene delivery, Bez et al . developed a two-step therapy. First, endogenous mesenchymal stem/progenitor cells were recruited to the bone nonunion by implanting a collagen sponge in the defect site. Two weeks later, bone morphogenetic protein-6 ( BMP-6 ) plasmid DNA and microbubbles were injected into nonunions, and ultrasound was applied to oscillate the microbubbles, which helped the recruited progenitors take up the BMP-6 . This therapy led to transient BMP-6 secretion, bone regeneration, and fracture healing over 6 weeks in critical-sized tibial nonunions in mini-pigs.
BigField GEG Tech's insight:
The Raf–MEK–ERK kinase pathway, which mediates cellular responses to a variety of extracellular signals, is regulated by positive and negative feedback mechanisms ranging from receptor degradation to transcriptional induction of inhibitory phosphatases. However, detecting these effects with temporal precision remains difficult. Zhou et al. engineered photodissociable dimeric variants of the Dronpa fluorescent protein (pdDronpa) that monomerize with cyan-light (500 nm) exposure and then attached pdDronpa domains to two locations on the Raf1 kinase domain. The interaction of the two pdDronpa domains under basal conditions prevents substrate access, while cyan-light exposure promotes dissociation, enabling kinase activity. This effect was reversible such that pdDronpa dimerization was restored with violet light (400 nm), inactivating kinase activity. Zhou et al. characterized a fast negative feedback mechanism on MEK, showing that a pulse of MEK activation by pdDronpa-modified Raf1 was followed by dephosphorylation attributable to ERK-mediated activation of protein phosphatases. Finally, the application of this technology to other kinases such as CDK5 provides additional support that pdDronpa may be a generally useful reagent for spatiotemporal control of kinase signaling.
Diamond-Blackfan anemia is a congenital erythroid hypoplasia. Twenty-five percent
BigField GEG Tech's insight:
In the present study, the scientists assessed the efficacy of a clinically relevant promoter, the human elongation factor 1α short promoter, with or without the locus control region of the β-globin gene for treatment of RPS19-deficient Diamond-Blackfan anemia. The findings demonstrate that these vectors rescue the proliferation defect and improve erythroid development of transduced RPS19-deficient bone marrow cells.
Non-union occurring in structural bone grafting is a major problem in allograft transplantation because of impaired interaction between the host and graft tissue.
BigField GEG Tech's insight:
In this study, the scientists evaluated the effects of local knockdown of the TLR4 signaling pathway in a mouse segmental femoral graft model. Allografts were coated with freeze-dried lentiviral vectors that encoded TLR4 and myeloid differentiation primary response gene 88 (MyD88) short-hairpin RNA (shRNA), which were individually transplanted into the mice. Their results show that inhibition of TLR4 and MyD88 might reduce immune responses and ameliorate allograft rejection.
BigField GEG Tech's insight:
In this study, the scientists induce ZEB1 gain-of-function experiments in MCF-7 cells and loss-of-function experiments in MDA-MB-231 cells thanks to lentiviral vectors. They report that ectopic zinc-finger E-box binding homeobox 1 (ZEB1) is associated with ER-α deficiency in breast cancer cells and thus confers antiestrogen resistance. Mechanistically, ZEB1 represses ER-α transcription by forming a ZEB1/DNA methyltransferase (DNMT)3B/histone deacetylase (HDAC)1 complex on the ER-α promoter, leading to DNA hypermethylation and the silencing of ER-α. Thus, ectopic ZEB1 downregulates ER-αexpression and subsequently attenuates cell growth inhibition by antiestrogens, such as tamoxifen and fulvestrant.
|
Your new post is loading...
In this study, the authors show that locoregional and systemic delivery of a rAAV2/8 vector expressing a canine microdystrophin (cMD1) is effective in restoring dystrophin expression and stabilizing clinical symptoms in studies performed on a total of 12 treated golden retriever muscular dystrophy (GRMD) dogs. Locoregional delivery induces high levels of microdystrophin expression in limb musculature and significant amelioration of histological and functional parameters.